1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Global Gene Therapy Market Forecast to 2020

Global Gene Therapy Market Forecast to 2020

  • January 2016
  • -
  • RNCOS
  • -
  • 190 pages

Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others.

According to RNCOS’ new research report “Global Gene Therapy Market Forecast to 2020”, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. Primarily, the gene therapy market is dominated by oncology applications, with several companies and academic institutions focusing on novel and ‘difficult to treat’ cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. Furthermore, the chapter also provides details regarding the various aspects of the clinical trials in the different gene therapy application by phases, vector types, etc.

The major part of the revenue of gene therapy market is generated from research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia, and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry’s growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understand the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Table Of Contents

Global Gene Therapy Market Forecast to 2020
1. Analyst View
2. Research Methodology
3. Gene Therapy - An Introduction
3.1 Classification of Gene Therapy Techniques
3.2 Physical Methods of Gene Transfer
3.2.1 Electroporation
3.2.2 Hydrodynamic
3.2.3 Microinjection
3.2.4 Particle Bombardment
3.2.5 Ultrasound-Mediated Transfection
3.3 Vectors for Gene Therapy
3.3.1 Viral Vectors
3.3.2 Non Viral Vectors
4. Industry Overview
4.1 Market Drivers
4.1.1 Failure of Conventional Therapies to Treat Cancers
4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
4.1.4 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 Stringent Regulatory Laws and Safety Concerns
4.2.2 Pitfalls in Current Technique
4.2.3 High Cost of the Gene Therapy Drugs
4.3 Market Opportunities
4.3.1 Approval of Gene Therapy Drug in Europe
4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
4.4 Industry Trends
4.4.1 Gene Silencing: Gaining Momentum
4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
4.4.4 Nanotechnology: Empowering Gene Therapy
4.4.5 Gene Therapy: A New Hope to Treat Blindness
4.4.6 Gene Therapy: Potential Cure for Cancer
4.5 Winning Imperatives
4.5.1 Investment in RandD Activities
5. Clinical Trial Assessment and Pipeline Analysis
5.1 Clinical Trials
5.1.1 By Geography
5.1.2 By Indication
5.1.3 By Gene Type
5.1.4 By Vector
5.1.5 By Clinical Trial Phase
5.2 Pipeline Analysis
6. Gene Therapy Market - Regulatory Landscape and Reimbursement Scenario
6.1 Regulatory Landscape
6.1.1 US
6.1.2 Canada
6.1.3 Europe
6.1.4 Japan
6.1.5 China
6.1.6 India
6.1.7 Australia
6.2 Reimbursement Scenario in Global Market
7. Marketed Gene Therapies
7.1 Neovasculgen
7.2 Glybera
7.3 Gendicine, Rexin-G, Oncorine
7.3.1 Gendicine
7.3.2 Rexin G
7.3.3 Oncorine
8. Global Gene Therapy Market
9. Gene Therapy Market by Application
9.1 Oncology
9.1.1 Clinical Trials
9.1.1 Prevalence
9.1.3 Market Outlook
9.2 Cardiovascular Diseases
9.2.1 Clinical Trials
9.2.2 Prevalence
9.2.3 Market Outlook
9.3 Infectious Diseases
9.3.1 Clinical Trials
9.3.2 Prevalence
9.3.3 Market Outlook
9.4 Neurological Diseases
9.4.1 Clinical Trials
9.4.2 Prevalence
9.4.3 Market Outlook
9.5 Genetic Diseases
9.5.1 Clinical Trials
9.5.2 Prevalence
9.5.3 Market Outlook
9.6 Others
9.6.1 Clinical Trials
9.6.2 Prevalence
9.6.3 Market Outlook
10. Global Gene Therapy Market Size by Geography
10.1 North America
10.2 Europe
10.3 Asia
10.4 Rest of the World (RoW)
11. Competitive Landscape
11.1 Strategies Adopted by Various Players
11.1.1 Strategic Collaborations
11.1.2 Acquisitions
11.1.3 Funding and Investments
11.2 Companies Progress in Gene Therapy In 2015
12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths and Weaknesses)
12.1 Spark Therapeutics, LLC
12.2 ViroMed Co. Ltd. dba VM BioPharma
12.3 Advantagene Inc.
12.4 Bluebird Bio
12.5 Sanofi
12.6 Vical Inc.
12.7 Oxford BioMedica Plc
12.8 Genethon
12.9 uniQure N.V.
12.10 Human Stem Cells Institute
12.11 Shanghai Sunway Biotech Co. Ltd.
12.12 Sibiono GeneTech Co. Ltd.

List of Figures:

Figure 4-1: Global - Major Venture Capitalist Investments in Gene Therapy Product Development (Billion US$), 1999 to 2015
Figure 5-1: Global - Number of Approved Gene Therapy Clinical Trials (2005-July 2015)
Figure 5-2: Global - Geographical Distribution of Gene Therapy Clinical Trials by Continents (%)
Figure 5-3: Global - Geographical Distribution of Gene Therapy Clinical Trials by Countries (%)
Figure 5-4: Global - Gene Therapy Clinical Trials by Indication (%)
Figure 5-5: Global - Gene Therapy Clinical Trials by Types of Gene Transferred (%)
Figure 5-6: Global - Gene Therapy Clinical Trials by Vectors (%)
Figure 5-7: Global - Gene Therapy Clinical Trials by Phase (%)
Figure 6-1: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
Figure 6-2: Japan - Evaluation System of Gene Therapy Clinical Trial
Figure 7-1: Global - Neovasculgen Sales (Million US$), 2013 and 2014
Figure 8-1: Global - Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 9-1: Global - Gene Therapy Market by Application (%), 2015
Figure 9-2: Global - Gene Therapy Market by Application (%), 2020
Figure 9-3: Global - Oncology Gene Therapy Clinical Trials by Vectors (%)
Figure 9-4: Global - Oncology Gene Therapy Clinical Trials by Phase (%)
Figure 9-5: Global - Oncology Gene Therapy Clinical Trials by Type (%)
Figure 9-6: Global - Oncology Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 9-7: Global - Oncology Gene Therapy Market by Geography (%), 2015
Figure 9-8: Global - Key Cardiovascular Diseases Gene Therapy Ongoing Clinical Trials
Figure 9-9: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Vectors (%)
Figure 9-10: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Phase (%)
Figure 9-11: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-12: Global - Cardiovascular Disease Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 9-13: Global - Cardiovascular Disease Gene Therapy Market by Geography (%), 2015
Figure 9-14: Global - Infectious Disease Gene Therapy Clinical Trials by Vectors (%)
Figure 9-15: Global - Infectious Disease Gene Therapy Clinical Trials by Phase (%)
Figure 9-16: Global - Infectious Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-17: Global - Infectious Disease Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 9-18: Global - Infectious Disease Gene Therapy Market by Geography (%), 2015
Figure 9-19: Global - Neurological Diseases Gene Therapy Clinical Trials by Vector (%)
Figure 9-20: Global - Neurological Diseases Gene Therapy Clinical Trials by Phase (%)
Figure 9-21: Global - Neurological Diseases Gene Therapy Clinical Trials by Type (%)
Figure 9-22: Global - Neurological Disease Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 9-23: Global - Neurological Disease Gene Therapy Market by Geography (%), 2015
Figure 9-24: Global - Genetic Disease Gene Therapy Clinical Trials by Vector (%)
Figure 9-25: Global - Genetic Disease Gene Therapy Clinical Trials by Phase (%)
Figure 9-26: Global - Genetic Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-27: Global - Genetic Disease Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 9-28: Global - Genetic Disease Gene Therapy Market, by Geography (%), 2015
Figure 9-29: Global - Other Disease Gene Therapy Clinical Trials by Type (%)
Figure 9-30: Global - Other Disease Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 9-31: Global - Other Disease Gene Therapy Market by Geography (%), 2015
Figure 10-1: Global - Gene Therapy Market by Geography (%), 2015
Figure 10-2: North America - Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 10-3: Europe - Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 10-4: Asia - Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 10-5: Asia - Number of Gene Therapy Laboratories by Major Asian Countries (2014)
Figure 10-6: India - Number of Gene Therapy Laboratories (2000, 2010 and 2013)
Figure 10-7: Rest of the World - Gene Therapy Market (Million US$), 2014, 2015 and 2020
Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
Figure 11-4: Key Players Focusing on Funding and Investments (2013 to 2015)
Figure 11-5: Companies Progress in Gene Therapy till 2015

List of Tables:

Table 4-1: US - Gene Therapies under Development
Table 4-2: Europe - Gene Therapies under Development
Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
Table 4-4: Current Status of Clinical Trials for Hemophilia
Table 5-1: Human Gene Transfer Trials Approved by Condition
Table 5-2: Global - Key Gene Therapy Ongoing Clinical Trials
Table 6-1: China - Key Players and their Products in Gene Therapy
Table 9-1: Global - Key Oncology Gene Therapy Ongoing Clinical Trials
Table 9-2: Global - Oncology Incidence by Geography (‘000), 2015 and 2020
Table 9-3: Global - Key Infectious Disease Gene Therapy Ongoing Clinical Trials
Table 9-4: Global - HIV Prevalence and Incidence by Geography (‘000), 2014
Table 9-5: Global - Key Neurological Disease Gene Therapy Ongoing Clinical Trials
Table 9-6: Global - Parkinson Disease Prevalence by Geography (Million), 2010
Table 9-7: Global - Key Genetic Disease Gene Therapy Ongoing Clinical Trials
Table 9-8: Global - Hemophilia Prevalence by Geography, 2010 and 2013
Table 9-9: Global - Key Other Disease Gene Therapy Ongoing Clinical Trials
Table 12-1: Spark Therapeutics LLC - Clinical Pipeline in Gene Therapy
Table 12-2: ViroMed Co. Ltd. - Clinical Pipeline in Gene Therapy
Table 12-3: Advantagene Inc. - Clinical Pipeline in Gene Therapy
Table 12-4: Bluebird Bio - Clinical Pipeline in Gene Therapy
Table 12-5: Sanofi - Clinical Pipeline in Gene Therapy
Table 12-6: Vical Inc. - Clinical Pipeline in Gene Therapy
Table 12-7: Oxford Biomedica Plc - Clinical Pipeline in Gene Therapy
Table 12-8: Genethon - Clinical Pipeline in Gene Therapy
Table 12-9: UniQure N.V. - Clinical Pipeline in Gene Therapy
Table 12-10: Human Stem Cells Institute - Clinical Pipeline in Gene Therapy
Table 12-11: Shanghai Sunway Biotech Co. Ltd. - Clinical Pipeline in Gene Therapy
Table 12-12: Sibiono GeneTech Co. Ltd. - Clinical Pipeline in Gene Therapy

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Regenerative medicines are capable of restoring the functionality of cells & tissues by treating a patient with laboratory grown cells and tissues. Regenerative medicines are used in a wide range of degenerative ...

Global Gene Therapy Partnering Terms and Agreements 2010 to 2016

Global Gene Therapy Partnering Terms and Agreements 2010 to 2016

  • $ 2995
  • Industry report
  • October 2016
  • by Currentpartnering

The Global Gene Therapy Partnering Agreements 2010-2016 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. ...

Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026

Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026

  • $ 2349
  • Industry report
  • October 2016
  • by Roots Analysis Private Ltd.

INTRODUCTION Gene therapy has emerged as a promising treatment option for various diseases (primarily the ones that currently have no cure) including cancers, inherited disorders and some viral infections. ...


Download Unlimited Documents from Trusted Public Sources

Global Tissue Engineering Markets

  • November 2016
    34 pages
  • Tissue Engineer...  

    Cell Therapy  

    Skin Care  

  • United States  

    World  

View report >

Biological Therapy Industry in the US

  • November 2016
    10 pages
  • Fig  

  • United States  

View report >

Global Nanomedicine Industry - Forecast

  • November 2016
    23 pages
  • Nanomedicine  

    Personal Genomi...  

    Gene Therapy  

  • United States  

    World  

    Japan  

View report >

Cell Therapy Industry

3 months ago

Related Market Segments :

Gene Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.